This article is more than 5 years old. Information may no longer be current.
Study: Company sponsorship of glaucoma drug trials did not affect IOP measurements at 1 month
Click Here to Manage Email Alerts
BOSTON — IOP measurements in randomized controlled trials investigating prostaglandin analogues do not appear to be affected by sponsorship of the study, whether by parent company, competing company or non-industry source, a study found.
"Pharmaceutical company sponsorship of [randomized clinical trials] for prostaglandin analogues did not bias IOP outcomes at 1 month. There was no evidence of short-term bias in the IOP measurements," Yvonne M. Buys, MD, and colleagues said in a poster study presented here at the World Glaucoma Congress.
Dr. Buys and colleagues examined 473 prostaglandin studies of Xalatan (latanoprost 0.005%, Pfizer), Lumigan (bimatoprost 0.03%, Allergan) and Travatan (travoprost, Alcon). After initial research, they narrowed their analysis to 34 of 43 publications investigating latanoprost. Of those studies, 14 were sponsored by the drug's parent company, five by a competing company and 15 by non-industry sources.
The study authors found that mean baseline IOP between the three groups was not significantly different, nor was the mean IOP reached at 1 month.
Also, mean change in IOP from baseline to 1 month was not different for the three groups.